These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
164 related articles for article (PubMed ID: 38896941)
1. Immune checkpoint inhibition in early-stage non-small cell lung cancer. Cuppens K; Du Pont B; Knegjens J; Maes B; Baas P Lung Cancer; 2024 Jul; 193():107855. PubMed ID: 38896941 [TBL] [Abstract][Full Text] [Related]
2. The role of immunotherapy in early-stage and metastatic NSCLC. Lieber A; Makai A; Orosz Z; Kardos T; Isaac SJ; Tornyi I; Bittner N Pathol Oncol Res; 2024; 30():1611713. PubMed ID: 39027681 [TBL] [Abstract][Full Text] [Related]
3. [Operability and Pathological Response of Non-Small Cell Lung Cancer (NSCLC) after Neoadjuvant Therapy with Immune Checkpoint Inhibition]. Lücke E; Ganzert C; Föllner S; Wäsche A; Jechorek D; Schoeder V; Walles T; Genseke P; Schreiber J Pneumologie; 2020 Nov; 74(11):766-772. PubMed ID: 32820489 [TBL] [Abstract][Full Text] [Related]
4. The new era of immune checkpoint inhibition and target therapy in early-stage non-small cell lung cancer. A review of the literature. Catania C; Muthusamy B; Spitaleri G; Del Signore E; Pennell NA Clin Lung Cancer; 2022 Mar; 23(2):108-115. PubMed ID: 34952792 [TBL] [Abstract][Full Text] [Related]
5. Pharmacodynamics of Pre-Operative PD1 checkpoint blockade and receptor activator of NFkB ligand (RANKL) inhibition in non-small cell lung cancer (NSCLC): study protocol for a multicentre, open-label, phase 1B/2, translational trial (POPCORN). Ahern E; Cubitt A; Ballard E; Teng MWL; Dougall WC; Smyth MJ; Godbolt D; Naidoo R; Goldrick A; Hughes BGM Trials; 2019 Dec; 20(1):753. PubMed ID: 31856909 [TBL] [Abstract][Full Text] [Related]
6. Immune Checkpoint Inhibitors in Early-Stage and Locally Advanced Non-Small Cell Lung Cancer. Puri S; Shafique M; Gray JE Curr Treat Options Oncol; 2018 Jun; 19(8):39. PubMed ID: 29931587 [TBL] [Abstract][Full Text] [Related]
7. The Value of Perioperative Immunotherapy for Non-Small Cell Lung Cancer: A Pool- and Meta-Analysis. Wu Y; Hu L; Zhang S; Zhang H Technol Cancer Res Treat; 2024; 23():15330338241258164. PubMed ID: 38872482 [No Abstract] [Full Text] [Related]
8. Adjuvant and Neoadjuvant Immunotherapy in Non-small Cell Lung Cancer. Broderick SR Thorac Surg Clin; 2020 May; 30(2):215-220. PubMed ID: 32327180 [TBL] [Abstract][Full Text] [Related]
10. Perioperative Immunotherapy for Non-Small Cell Lung Cancer: Practical Application of Emerging Data and New Challenges. D'Aiello A; Stiles B; Ohri N; Levy B; Cohen P; Halmos B Clin Lung Cancer; 2024 May; 25(3):197-214. PubMed ID: 38462413 [TBL] [Abstract][Full Text] [Related]
11. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer. Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104 [TBL] [Abstract][Full Text] [Related]
15. Effects of checkpoint inhibitors in advanced non-small cell lung cancer at population level from the National Immunotherapy Registry. Smit HJM; Aerts J; van den Heuvel M; Hiltermann TJN; Bahce I; Smit EF; Dingemans AC; Hendriks LE; Stigt JA; Schramel FMNH; van Tinteren H; Groen HJM; Lung Cancer; 2020 Feb; 140():107-112. PubMed ID: 31911323 [TBL] [Abstract][Full Text] [Related]
16. Systematic review and meta-analysis of immune checkpoint inhibitors as single agent or in combination with chemotherapy in early-stage non-small cell lung cancer: Impact of clinicopathological factors and indirect comparison between treatment strategies. Nuccio A; Viscardi G; Salomone F; Servetto A; Venanzi FM; Riva ST; Oresti S; Ogliari FR; Viganò M; Bulotta A; Cameron R; Esposito A; Hines J; Bianco R; Reni M; Cascone T; Garassino MC; Torri V; Veronesi G; Cinquini M; Ferrara R Eur J Cancer; 2023 Dec; 195():113404. PubMed ID: 37948842 [TBL] [Abstract][Full Text] [Related]
17. Neoadjuvant chemotherapy and Avelumab in early stage resectable nonsmall cell lung cancer. Tfayli A; Al Assaad M; Fakhri G; Akel R; Atwi H; Ghanem H; El Karak F; Farhat F; Al Rabi K; Sfeir P; Youssef P; Mansour Z; Assi H; Haidar M; Abi Ghanem A; Khalifeh I; Boulos F; Mahfouz R; Youssef B; Zeidan Y; Bejjany R; Khuri F Cancer Med; 2020 Nov; 9(22):8406-8411. PubMed ID: 32991781 [TBL] [Abstract][Full Text] [Related]
18. Moving Immunotherapy Into the Treatment of Resectable Non-Small Cell Lung Cancer. Chaft JE; Dziadziuszko R; Haddock Lobo Goulart B Am Soc Clin Oncol Educ Book; 2024 Jun; 44(3):e432500. PubMed ID: 38788177 [TBL] [Abstract][Full Text] [Related]
19. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer. Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V Cochrane Database Syst Rev; 2021 Apr; 4(4):CD013257. PubMed ID: 33930176 [TBL] [Abstract][Full Text] [Related]
20. Current status of immune checkpoint inhibition in early-stage NSCLC. Vansteenkiste J; Wauters E; Reymen B; Ackermann CJ; Peters S; De Ruysscher D Ann Oncol; 2019 Aug; 30(8):1244-1253. PubMed ID: 31143921 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]